ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 189,13
0,13%
Dow Jones
44 546,08
-0,37%
DAX
22 798,09
1,40%
Brent Oil
75,065
1,12%
Bitcoin
95 686,09
-0,46%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Avadel Pharmaceuticals PLC (AVDL)

  7. Avadel Pharmaceuticals PLC (AVDL) Actualités

AVDL

Avadel Pharmaceuticals (AVDL)

Avadel Pharmaceuticals PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AVDL
DateHeureSourceTitreSymboleSociété
14/02/202517h55Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVDLAvadel Pharmaceuticals PLC
28/01/202522h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
22/01/202514h00GlobeNewswire Inc.Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and ReimbursementNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/01/202522h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/01/202522h15GlobeNewswire Inc.Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ LaunchNASDAQ:AVDLAvadel Pharmaceuticals PLC
06/01/202522h05GlobeNewswire Inc.Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AVDLAvadel Pharmaceuticals PLC
03/01/202514h00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8NASDAQ:AVDLAvadel Pharmaceuticals PLC
11/12/202414h00GlobeNewswire Inc.Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate TherapyNASDAQ:AVDLAvadel Pharmaceuticals PLC
14/11/202417h50Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVDLAvadel Pharmaceuticals PLC
13/11/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/11/202413h00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
04/11/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12NASDAQ:AVDLAvadel Pharmaceuticals PLC
31/10/202412h00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act LitigationNASDAQ:AVDLAvadel Pharmaceuticals PLC
24/10/202420h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVDLAvadel Pharmaceuticals PLC
24/10/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep AdvancesNASDAQ:AVDLAvadel Pharmaceuticals PLC
17/10/202415h41GlobeNewswire Inc.Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with NarcolepsyNASDAQ:AVDLAvadel Pharmaceuticals PLC
25/09/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting AgentNASDAQ:AVDLAvadel Pharmaceuticals PLC
03/09/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)NASDAQ:AVDLAvadel Pharmaceuticals PLC
28/08/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:AVDLAvadel Pharmaceuticals PLC
20/08/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral SuspensionNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202415h25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202413h00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8NASDAQ:AVDLAvadel Pharmaceuticals PLC
31/07/202422h05GlobeNewswire Inc.Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic HypersomniaNASDAQ:AVDLAvadel Pharmaceuticals PLC
27/06/202422h05GlobeNewswire Inc.Avadel Pharmaceuticals to Join Russell 3000® IndexNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202413h25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202413h17Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202413h11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AVDLAvadel Pharmaceuticals PLC
22/05/202414h00GlobeNewswire Inc.Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024NASDAQ:AVDLAvadel Pharmaceuticals PLC
21/05/202423h27Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:AVDL

Dernières Valeurs Consultées

EU
AI
Air Liquide
EU
VIV
Vivendi
EU
ACA
Credit Agricole
EU
GLE
Societe Generale
NYSE
JPM
JP Morgan Chase
NASDAQ
NVDA
NVIDIA
EU
RI
Pernod Ricard
NASDAQ
GOOGL
Alphabet
SPI
SP500
S&P 500
EU
HO
Thales
NYSE
KO
Coca Cola
EU
ORA
Orange
EU
EN
Bouygues
EU
BEL20
Bel 20
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces